NCT06651593View on ClinicalTrials.gov

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions

Solid Tumors

Interventions

DRUG

SAR444881

Given by IV

DRUG

Cemiplimab

Given by Iv

Trial Locations (1)

77030

RECRUITING

Md Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER